

LA200-3: Results Report Form for Clinical Field Trials using LIQUAMYCIN® LA-200® INAD #9027

INSTRUCTIONS

- Investigator must fill out Form LA200-3 no later than 10 days after completion of the post-treatment observation period. Study Number must be recorded on all pages of Form LA200-3. Attach lab reports and other information.
- If LIQUAMYCIN® LA-200® was not used under the assigned Study Number, fill out only the Site Information portion on this page, and skip to the end of page 4 and fill out only the "Negative Report" section.
- Investigator should keep the original on file, and send a copy to the Study Monitor. Within 10 days of receipt, the Study Monitor should send a copy to the AADAP Office for inclusion in the permanent file.
- Note:** Both Investigator and Study Monitor should sign and date Form LA200-3.

SITE INFORMATION

Facility	
Reporting Individual	

TREATMENT INFORMATION AND SCHEDULE

Drug lot number		Total amount drug used (mg)	
Fish species treated		OTC dosage used (mg OTC/Kg body weight)	20
Disease treated		Disease diagnosed by	
Average fish weight (gm)		Average fish length (in)	
Number of fish per unit (e.g. 100 fish/raceway)			
Number of treated units		Total number of treated fish	
Number of control units		Total number of control fish	
Number of sham-treated units		Total number of sham- treated fish (Hanks PBS)	
Number of injections/fish	1	Treatment date	

WATER QUALITY PARAMETERS

Ave pre-treatment temp (°F)		Dissolved Oxygen (mg/L)	
Ave treatment temp (°F)		pH	
Ave post-treatment temp (°F)		Hardness - CaCO ₃ (mg/L)	

Daily Mortality Record

INSTRUCTIONS

1. Investigator should fill out the Daily Mortality Record as completely as possible.
2. Prior to initiation of the trial, fill out Rearing Unit ID, whether a rearing unit is Treated or Control, and the number of fish in each rearing unit.
3. Water temperature and individual tank mortality should be recorded on a daily basis.
4. Please mark all treatment days with an asterisk.
5. Use additional copies of this form if more than 6 rearing units are involved in the trial.

FACILITY										
	Rearing Unit ID									
	Treated or Control									
	Number of Fish									
	Day	Date	Water Temp (F°)	Mortality	Mortality	Mortality	Mortality	Mortality	Mortality	Mortality
Pre-treatment period	1									
	2									
	3									
	4									
	5									
Treatment period	1									
Post-treatment period	1									
	2									
	3									
	4									
	5									
	6									

FACILITY										
	Rearing Unit ID									
	Treated or Control									
	Number of Fish									
	Day	Date	Water Temp (F°)	Mortality	Mortality	Mortality	Mortality	Mortality	Mortality	Mortality
Post-treatment period	7									
	8									
	9									
	10									
	11									
	12									
	13									
	14									
	15									
	16									
	17									
	18									
	19									
	20									
21										

RESULTS: Describe in detail treatment results. Was treatment successful? If treatment did not appear to be successful, explain why not? Were there any mitigating environmental conditions that may have impacted treatment results? Were there any deviations from the Study Protocol?

Pathology Report: Attach pathology report to this form. Report should include: 1) a description of how the pathogen(s) was identified; 2) disease identification records that confirm the presence of the pathogen; and 3) the name and title of the individual performing the diagnosis.

Pathology Report included: pre-treatment post-treatment

Toxicity observations: Report any apparent drug toxicity including a description of unusual fish behavior.

OBSERVED WITHDRAWAL PERIOD OF TREATED FISH:

Observed withdrawal period:

<input type="checkbox"/>
<input type="checkbox"/>

Study Objective A - Withdrawal period of 30 days for variety of salmonid fish. Single injection at 20 mg OTC/Kg body weight.

Study Objective B - Withdrawal period of 30 days for non-salmonid fish. Single injection at 20 mg OTC/Kg body weight.

Estimated number of days between last treatment and first availability of fish for human consumption (ensure this time period meets the withdrawal period). _____

NEGATIVE REPORT LIQUAMYCIN® LA-200® was not used at this facility under this Study Number during the reporting period. (Investigator should initial for negative reports as soon as the Study Number is known to be no longer needed or valid.)

Date Prepared: _____ **Investigator:** _____

Date Reviewed: _____ **Study Monitor:** _____